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IL-4 and IL-10 Antagonize IL-12-Mediated Protection Against
Acute Vaccinia Virus Infection with a Limited Role of IFN-g
and Nitric Oxide Synthetase 21
Maries van den Broek,* Martin F. Bachmann,† Gabriele Ko¨hler,‡ Marijke Barner,†
Ru¨diger Escher,§ Rolf Zinkernagel,* and Manfred Kopf2†
Resistance or susceptibility to most infectious diseases is strongly determined by the balance of type 1 vs type 2 cytokines produced
during infection. However, for viruses, this scheme may be applicable only to infections with some cytopathic viruses, where IFN-g
is considered as mandatory for host defense with little if any participation of type 2 responses. We studied the role of signature
Th1 (IL-12, IFN-g) and Th2 (IL-4, IL-10) cytokines for immune responses against vaccinia virus (VV). IL-122/2 mice were far
more susceptible than IFN-g2/2 mice, and primary CTL responses against VV were absent in IL-122/2 mice but remained intact
in IFN-g2/2 mice. Both CD41 and CD81 T cells from IL-122/2 mice were unimpaired in IFN-g production, although CD41 T
cells showed elevated Th2 cytokine responses. Virus replication was impaired in IL-42/2 mice and, even more strikingly, in
IL-102/2 mice, which both produced elevated levels of the proinflammatory cytokines IL-1a and IL-6. Thus, IL-4 produced by
Th2 cells and IL-10 produced by Th2 cells and probably also by macrophages counteract efficient anti-viral host defense. Sur-
prisingly, NO production, which is considered as a major type 1 effector pathway inhibited by type 2 cytokines, appears to play
a limited role against VV, because NO sythetase 2-deficient mice did not show increased viral replication. Thus, our results identify
a new role for IL-12 in defense beyond the induction of IFN-g and show that IL-4 and IL-10 modulate host protective responses
to VV. The Journal of Immunology, 2000, 164: 371–378.
C D41 (Th) cells can be divided into at least two subsets ofeffector cells, termed Th1 and Th2, with contrasting cy-tokine profiles. Immune responses are often polarized, as
cytokine secretion from one subset inhibits the development of the
other (1). The distinctive cytokine profiles can be correlated well
with functional differences of the two subsets, which has provided
a concept for how the immune system combats such diverse patho-
gens as bacteria, protozoa, fungi, and helminthic parasites (2).
Anti-viral defense has been less dominated by the Th1-Th2 par-
adigm, because CD81 effector T cells are key mediators for clear-
ance of noncytopathic viruses through cytolysis of infected cells
and for clearance of cytopathic viruses through secretion of IFN-g
and TNF-a, which exert direct anti-viral activity (3, 4). Depending
on the type of virus infection, CD41 T cells promote protection by
providing help for B cells (3) and CTL responses (5, 6). In addi-
tion, a role of CD41 subpopulations (Th1 vs Th2) has been sug-
gested, but is less well defined. For example, poliovirus-specific
Th1 clones mediate protective immunity against a lethal poliovirus
infection in a transgenic mouse model of poliomyelitis (7). CD41
T cells and IFN-g can effectively clear mouse CMV infection in
the absence of CD81 T cells (8–10). Similarly, influenza virus
infection can be cleared in the absence of CD81 T cells (11), and
Th1-specific anti-influenza clones protect against infection,
whereas Th2 clones exacerbate pulmonary pathology (12). During
measles virus infection, T cells show a biased Th2 response, which
can be explained by the ability of the virus to suppress cell-medi-
ated immunity and IL-12 production of dendritic cells and mono-
cytes (13, 14). A prominent example is the case of HIV infection,
where progression to AIDS may be associated with a Th1 to Th2
switch in a subset of patients (15, 16). In all of these examples, it
has been suggested that Th1 responses promote viral clearance.
IL-12 is the key cytokine for the induction of Th1 development
(17), and IL-12 treatment has been shown to promote protective
immunity to a variety of viruses including encephalomyocarditis
virus (18), murine CMV (19), murine AIDS virus (20), lympho-
cytic choriomeningitis virus (LCMV)3 (21), and hepatitis B virus
(22). In contrast, experiments with IL-122/2 mice showed that
endogenous IL-12 is not required for the control of mouse hepatitis
virus (23) and LCMV infection (24).
Cell-mediated immune responses to microbial pathogens can be
inhibited by Th2 cells. The best studied example is infection with
Leishmania major, where IL-4 is responsible for fatal disease in
susceptible BALB/c mice. Studies with viral infection systems
have shown that overexpression of IL-4 using either recombinant
vaccinia virus (VV) as a vector, IL-4 transgenic mice, or treatment
with recombinant IL-4 was detrimental for the host during infec-
tion with VV (25), respiratory syncytial virus (26), and influenza
virus (27). Further, transfer of influenza-specific Th2 clones delays
virus clearance and exacerbates pulmonary pathology (12). Inter-
estingly, several studies with IL-42/2 mice have failed to support
a role of this cytokine in viral pathology (28–30).
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IL-10, a cytokine secreted mainly by Th2 cells and macro-
phages, is a potent inhibitor of the inflammatory response and Th1
polarization during bacterial and parasitic diseases. Hardly any-
thing is known about the role of IL-10 during virus infections,
although the incorporation of the human IL-10 gene into the EBV
genome (31) suggests that this cytokine may be important for the
virus to evade host defense. However, the few studies that ad-
dressed this issue suggested that IL-10 does not interfere with virus
clearance (32, 33).
Type 1 and type 2 cytokines have been shown to differentially
regulate NO production. The release of NO by activated macro-
phages and neutrophils is one of the major defense weapons
against many pathogens (34) including a number of viruses such as
ectromelia virus (35), HSV (36), EBV (37), and coxsackie virus
(38). However, the role of NO during VV infection appears in-
triguing. While NO can interrupt VV replication (39), and a re-
combinant VV encoding NO synthetase 2 (NOS2) is highly atten-
uated (40), pharmacologic inhibition of NO during VV infection
does not alter the course of infection (41). Because pharmacologic
inhibitors also affect NOS1 and NOS3, a detailed study on the role
of NOS2 in combination with its major cytokine regulators re-
mains to be done.
In this study, we have analyzed effector responses and virus
clearance in C57BL/6 mice deficient for key type 1 cytokines (IL-
12, IFN-g) and type 2 cytokines (IL-4, IL-10), and for inducible
NO synthase following infection with VV. VV is the representa-
tive member of the poxvirus family of cytoplasmic DNA viruses.
VV induces cytolytic infections and is an expert in exploiting the
cytokine network for immune evasion (42). Our results demon-
strate that endogenous type 1 and type 2 cytokine responses cross-
regulate immunity to acute VV infection with IL-12 and IL-10 as
the dominant factors for resistance and susceptibility, respectively.
Materials and Methods
Mice
IL-42/2 mice (43), IL-102/2 mice (44) (kindly provided by W. Mu¨ller,
Cologne, Germany), IFN-g2/2 mice (45) (kindly provided by Genentech,
South San Francisco, CA), IL-12p352/2 mice (46) (kindly provided by J.
Magram, Nutley, NJ), and NOS22/2 mice (47) (kindly provided by M.
Modollel with the permission of J. Mudgett) were generated as described.
Mutant mouse strains used for the experiments were back-crossed for six
to eight generations to C57BL/6. Genotypes were determined by PCR am-
plification of DNA prepared from tail biopsies with specific oligonucleo-
tide primers for IL-4 (forward, GTG AGC AGA TGA CAT GGG GC;
reverse, CTT CAA GCA TGG AGT TTT CCC), IL-10 (forward, CAA
AGC CAC AAG GCA GCC TTG; reverse, GAC AGT GCT AGA GCC
CGG AGT), IFN-g (forward, AGA AGT AAG TGG AAG GGC CCA
GAA G; reverse, AGG GAA ACT GGG AGA GGA GAA ATA T), IL-
12p35 (wild-type allele: forward, AGC TCC TCT CAG TGC CGG TC;
reverse, GGT CTT CAG CAG GTT TCG GG; mutant allele: forward,
GGC TCT GGA CTC ACC TGG AT; reverse, GCA TCG CAT TGT CTG
AGT AGG), NOS2 (wild-type allele: forward, TCA CGC TTG GGT CTT
GTT CAC; reverse, CAG GTC ACT TTG GTA GGA TTT; mutant allele:
forward, GCA ATG TGA CAA AGC TCC TTC AG; reverse, GAA GAA
CGA GAT CAG CAG CCT C). Mice were maintained in a facility free of
specific pathogens at the Basel Institute for Immunology. C57BL/6 wild-
type mice were purchased from IFFA-Credo (Saint Germain-sur-l‘Abresle,
France). For experiments, 8- to 12-wk-old female mice were used and kept
in microisolator cages. At the time of experiments, 8-wk-old IL-102/2
mice showed no obvious signs of colitis.
Viruses and virus titration
VV strain Western Reservate (WR) and recombinant VV expressing either
murine IL-4 (25), murine IFN-g (48), or the LCMV glycoprotein (VV-G2)
were grown at a low multiplicity of infection on BSC40 cells and plaqued
on BSC40 cells. VV-IL-4 and VV-IFN-g were kindly provided by A. Ram-
say (Canberra, Australia). VV-G2 was used as a control recombinant VV,
because G2 derived from LCMV is irrelevant for the anti-VV response.
Mice were infected with 2 3 106 pfu VV i.p., unless stated otherwise, and
sacrificed by CO2. For determination of viral titers, lungs and ovaries were
frozen at indicated days of harvest from mice and then thawed and ho-
mogenized in 2 ml MEM plus 2% FCS just before use in plaque assays.
Tenfold dilutions were plaqued on monolayers of BSC40 cells in 24-well
plates. Plates were stained after 48 h with crystal violet, and plaques were
counted.
Cytotoxic T cell assay
Six days after infection, spleens were taken out and a single-cell suspension
was made. Splenocytes were adjusted to 9 3 106 cells/ml. Target cells
(MC57G H-2b fibroblasts) were infected with VV-WR (multiplicity of in-
fection, 3) for 3 h at 37°C. During the last 90 min of the infection, 51Cr-
NaCrO4 was added. Threefold dilutions of effector cells were incubated for
6 h at 37°C with 104 target cells in 200-ml cultures. The percentage specific
51Cr release was calculated as: % specific lysis 5 [(experimental release 2
spontaneous release)/(maximum release 2 spontaneous release)] 3 100%.
Separation and stimulation of cells
Spleens were removed at day 7 after infection, teased to single-cell sus-
pensions, and CD41 and CD81 (mAb 53–6.72) T cells were purified by
magnetic cell separation (MACS; Miltenyi Biotec, Bergisch-Gladbach,
Germany). Cells were incubated with CD4 mAb or CD8 mAb coupled to
magnetic beads according to the manufacturer’s instructions and sorted
using MACS columns and the MidiMACS system. Aliquots of the unsorted
and sorted cell fractions were analyzed by flow cytometry. CD41 and
CD81 T cell populations were sorted to a purity of 80–90%. Cells were
kept on ice until further use for in vitro cell culture. Purified cell popula-
tions and unsorted splenocytes from infected mice were plated (2 3 105/0.2
ml) in flat-bottom microtiter plates (Costar, Cambridge, MA) precoated
with anti-CD3 mAb 145–2C11 (10 mg/ml) and cultured for 48 h. Cytokine
levels in the supernatant were determined by sandwich ELISA for IL-4,
IL-10, IFN-g (PharMingen, San Diego, CA), IL-1a, and IL-6 (Genzyme,
Cambridge, MA).
Histology
On day 6 after infection, lungs were isolated, fixed in 4% neutral buffered
formalin, and paraffin embedded. Tissue sections (5 mm) were stained with
hemotoxylin and eosin and analyzed microscopically. Photographs were
taken with a Zeiss Axiophoto photomicroscope (Zeiss, Oberkochen,
Germany).
Results
IL-12 is more important than IFN-g for clearance of VV
infection
To study the role of key type 1 cytokines on the susceptibility
to infection with a cytopathic DNA virus, IL-12p352/2 mice,
IFN-g2/2 mice, and C57BL/6 wild-type controls were infected
with 106 pfu VV (WR), and virus titers were determined in ova-
ries, where VV replicates most extensively. VV clearance was
markedly impaired in IL-122/2 mice, which showed a 20-fold and
100-fold increased viral load at days 3 and 6 after infection as
compared with controls (Fig. 1). Virus titers were also highly el-
evated (10- to 20-fold) after infection with low-dose (104 pfu) VV
(WR) (not shown). In contrast, clearance of VV (WR) was not
severely affected in IFN-g2/2 mice throughout the course of in-
fection (Fig. 1). Interestingly, after infection with a recombinant
VV (VV-G2) (see Fig. 4), which is attenuated due to a targeted
mutation of the thymidine kinase gene, virus titers in ovaries of
IFN-g2/2 mice were ;10- to 50-fold increased compared with
controls. Thus, our results demonstrate the IL-12 response to VV
infection (25) is crucial for host defense, whereas IFN-g appears
neither required for virus clearance nor for the induction and
reinforcement of this IL-12 response. However, dependent on the
virulence of infection, IFN-g can contribute to anti-viral immunity.
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Endogenous IL-4 and IL-10 inhibit clearance of VV infection
It has been well established that IL-4 and IL-10 can inhibit type 1
responses and prevent clearance of some pathogens (2). To assess
the role of these cytokines during infection with VV, we measured
virus titers in ovaries of IL-42/2 mice, IL-102/2 mice (both
C57BL/6), and wild-type mice infected with varying doses (104,
106, and 108 pfu) of VV (WR) or with 106 pfu of recombinant
VV-G2. A dose of 108 pfu was lethal for wild-type mice (3/3) and
for IL-42/2 mice (2/3). In contrast, IL-102/2 mice showed a dra-
matically reduced virus titer ranging between 103- to 104-fold after
infection with low, intermediate, and high doses of VV (WR) and
VV-G2 at day 6 after infection (Fig. 2). Virus titers were reduced
10- to 20-fold as early as day 3 after infection. In IL-42/2 mice,
virus titers in ovaries were reduced 80-fold after infection with 106
pfu VV (WR), whereas virus replication was not significantly dif-
ferent after infection with low doses (104 pfu) of VV (WR) or with
106 pfu of VV-G2 (Fig. 2). These results demonstrate that endog-
enous IL-4 and, in particular, IL-10 inhibit VV clearance. IL-4
production depends mainly on differentiated type 2 effector T cells
producing a panel of type 2 cytokines including IL-10, suggesting
that IL-4 may be important later in infection during the acquired
response. In contrast, IL-10 can be produced by, and act as an
autocrine inhibitor of, macrophages early after infection, which
may explain the finding that IL-10 is more potent than IL-4 in
suppression of host defense.
IFN-g production does not require IL-12
Studies with mice deficient for IL-4 (43), IL-4Ra (49, 50), and
STAT6 (51–53), the IL-4-activated signal transducer, have dem-
onstrated an important role for IL-4 in the development of Th2
cells. Vice versa, mice deficient for IL-12 (46), IL-12Rb1 (54),
and STAT4 (55, 56), the IL-12-activated signal transducer, high-
lighted a critical role of IL-12 in the development of IFN-g-se-
creting Th1 cells. To determine cytokine patterns in virus-infected
mice, we purified splenic CD41 and CD81 cells from infected
mice and measured IL-4, IL-10, and IFN-g production after re-
stimulation with anti-CD3. As shown in Fig. 3A, C57BL/6 mice
mounted a strong type 1 response with IFN-g produced by both
CD41 and CD81 T cells. IL-4 was produced by CD41 T cells
only, while IL-10 was secreted by CD41 and to a lower extent also
from CD81 T cells. CD41 T cells in IL-122/2 mice showed aug-
mented type 2 cytokine responses (e.g., IL-4 and IL-10), but also
a slightly increased IFN-g response. CD81 T cell cytokine pro-
duction was unaltered in the absence of IL-12. CD41 T cells from
IL-42/2 mice produced lower amounts of IL-10 but normal IFN-g,
indicating impaired Th2 without reciprocal increase in Th1 devel-
opment. In contrast, Th1 development was markedly increased in
IL-10-deficient mice. Next, we examined CD41 and CD81 T cells
from bronchoalveolar lavage of infected mice. As determined by
intracellular staining, the frequency of IFN-g-producing CD41 T
cells was unaltered in IL-42/2 mice (Fig. 3B), but was consider-
ably enhanced in IL-102/2 mice and also slightly elevated in IL-
122/2 mice (Fig. 3B), essentially in consistence with measure-
ments in supernatants from restimulated splenic CD41 T cells.
Thus, as might be predicted, we find enhanced Th1 development in
the absence of IL-10 and impaired Th2 development in the absence
of IL-4. Surprisingly, IFN-g production was not significantly in-
fluenced by the absence of IL-12 or IL-4 after vaccinia infection.
To assess the production of proinflammatory cytokines, we mea-
sured IL-1a and IL-6 in supernatants after anti-CD3 stimulation of
total splenocytes derived from groups of VV-infected mice. Both
IL-42/2 and IL-102/2 mice showed markedly increased levels of
both IL-1a and IL-6, (Fig. 3C), which demonstrates that both IL-4
and IL-10 are potent inhibitors of the proinflammatory cytokine
response against VV.
FIGURE 1. Impaired clearance of VV in IL-122/2 mice. Mice were
infected i.p. with 106 pfu of VV (WR) and sacrificed on days 3 and 6 to
collect ovaries for determination of virus titers. Shown are values of indi-
vidual mice. Data are representative of three separate experiments.
FIGURE 2. Enhanced clearance of VV in
IL-42/2 and IL-102/2 mice. Mice were in-
fected i.p. with doses indicated of VV (WR)
and VV-G2 and sacrificed on days 3 and 6
to collect ovaries for determination of virus
titers. Shown are values of individual mice.
Data are representative of two separate
experiments.
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IL-4 expressed by recombinant VV affects virus clearance by
inhibition of IL-12-dependent and IL-12-independent pathways
Ectopic expression of a cytokine exactly at the same time and
place where the immune response against the virus is initiated
allows one to study the potential effect of this cytokine on the
generation of specific immunity and the consequences for virus
control in vivo (57). To further understand the role of type 1 and
type 2 responses, the effector mechanisms, and their interrelation
during infection with VV, we infected wild-type and cytokine-
deficient mice with 106 pfu recombinant VV expressing IL-4 (VV-
IL-4), IFN-g (VV-IFN-g), or an irrelevant control protein (VV-
G2) and determined virus clearance (Fig. 4) and virus-specific
CTL responses (Fig. 5). In agreement with others, we found that
virus-expressed IL-4 exacerbates VV infection in mice (25). Virus
titers in ovaries of C57BL/6 mice were 100- to 1000-fold increased
(Fig. 4) and persisted much longer (.11 days, not shown). In-
creased viral load (3 log) and delayed clearance was also observed
in IL-42/2 mice, demonstrating that virus- but not host-encoded
IL-4 inhibits virus clearance. Notably, virus titers in IL-122/2
mice were higher after VV-IL-4 compared with VV-G2 infection,
suggesting that IL-4 inhibits other host defense pathways in addi-
tion to inhibition of IL-12. In contrast, the susceptibility of IL-
122/2 and IFN-g2/2 mice to VV was almost entirely reverted by
vector expressed IFN-g (VV-IFN-g).
CTL responses are abrogated in IL-122/2 mice but not in
IFN-g2/2 mice
To evaluate the role of type 1 and type 2 cytokines on the activity
of antiviral CTL responses, IL-122/2, IFN-g2/2, IL-102/2, and
IL-42/2 mice were infected with VV-G2 and primary ex vivo CTL
responses were measured at day 6, the peak time of anti-VV CTL
(Fig. 5). In agreement with others, we found that IFN-g is not
required for the generation of cytolytic effector cells during virus
infection (30, 58, 59). Indeed, vaccinia-specific CTL responses
were slightly elevated in IFN-g2/2 mice, which may be due to
enhanced proliferation of T cells in the absence of IFN-g (45, 59).
In contrast, CTL responses were virtually abrogated in infected
IL-122/2 mice. IL-42/2 and IL-102/2 mice infected with recom-
binant VV-G2 showed little differences compared with wild-type
mice. Basically the same results were obtained when the various
cytokine-deficient mice were infected with VV (WR), with the
exception of IL42/2 and IL-102/2 mice that showed slightly (;3-
fold) enhanced CTL responses (data not shown). It has been sug-
gested previously that IL-4 can suppress CD81 T cell cytotoxicity
in vitro and in vivo. In agreement with these results, we found that
CTL responses were abolished in immunocompetent mice infected
with VV-expressing IL-4 (VV-IL-4). Surprisingly, VV-IL-4 failed
to suppress CTL responses in IL-42/2 mice. In contrast, virus-
expressed IFN-g (VV-IFN-g) reconstituted CTL responses to al-
most normal levels in IL-122/2 mice, which may suggest that
FIGURE 3. Cytokine responses. A, Mice were infected i.p. with 2 3 106
pfu of VV (WR) and sacrificed on day 7 to collect spleens and the bron-
choalveolar lavage (BAL) for determination of cytokine production.
Splenic CD41 T cells (upper panel) and CD81 T cells (lower panel) were
purified by magnetic sorting and stimulated with immobilized anti-CD3 for
48 h before measurement of supernatants for IL-4, IL-10, and IFN-g by
ELISA. Shown are values of individual mice (open symbols) and the av-
erage of a group (filled symbols). B, BAL cells were stimulated with PMA
and inonomycin for 4 h. During the last 2 h Brefeldin was added to retain
cytokines in the cytoplasm. Cells were stained with APC-labeled anti-CD4,
FITC-labeled anti-CD8, and after permeabilization using saponin, with PE-
labeled anti-IFN-g (or IL-4) before analysis by three-color flow cytometry.
Shown is the percentage of CD41 and CD81 T cells producing IFN-g. The
frequency of IL-4-producing cells was below detection limit and is not
shown. C, Unpurified splenocytes were stimulated as described above, and
supernatants were measured for IL-1a and IL-6. Shown are average values
(n 5 3/group) from two different experiments.
FIGURE 4. Mice were infected i.p. with 2 3 106 pfu of either VV-G2,
VV-IL-4, or VV-IFN-g and sacrificed on day 6 to collect ovaries for de-
termination of virus titers. Shown are values of individual mice.
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tissue damage and possibly CD81 T cell exhaustion due to in-
creased viral replication is responsible for the lack of measurable
CTL responses in IL-122/2 mice.
Severe morphological lung damage in IL-122/2 mice
We next assessed the overall pulmonary inflammatory process of
mice infected with VV. Therefore, lung tissues from virus-infected
mice were analyzed histologically. Lung pathology in C57BL/6
mice infected with VV-G2 was confined to a few foci of perivas-
cular and peribronchial inflammation of lymphocytes, mononu-
clear, and some polymorphonuclear cells (Fig. 6). In contrast, in-
fection of C57BL/6 and IL-122/2 mice with VV-IL-4 and VV-G2,
respectively, profoundly altered the lung architecture, with exten-
sive inflammation and edema, and with damage of alveoli.
NO is dispensable for clearance of VV
NO production has been shown to be beneficial as an anti-viral
effector mechanism both in vitro and in vivo (34). Type 1 and type
2 cytokines are important regulators of NO production with an-
tagonizing activities. IFN-g and TNF-a are the main activators of
NOS2, the enzyme that catalyzes NO production, whereas type 2
cytokines, i.e., IL-4, IL-10, and IL-13, are potent inhibitors. Thus,
we hypothesized that the antagonizing effects of type 1 and type 2
cytokines on the control of VV infection may be mediated by
regulation of NO production. To test the role of NO for clearance
of acute VV infection, we studied NOS22/2 mice infected with
VV (WR). Viral growth in the ovaries was comparable in
NOS22/2 and C57BL/6 control mice at days 6 (Fig. 7), 8, and 10
(not shown), suggesting that NO production is not critical for con-
trol of VV infection.
Discussion
Our study demonstrates the first clear example where the balance
of endogenous type 1 and type 2 cytokines produced in response to
viral infection determines pathogen clearance and the severity of
disease. IL-122/2 and IFN-g2/2 mice were more susceptible,
whereas IL-42/2 and IL-102/2 mice were more resistant, to VV
infection compared with wild-type controls. IFN-g is considered as
a critical player in anti-viral immune responses, mainly based on
its direct anti-viral activity (4). However, in vivo studies have
demonstrated that the role of IFN-g in anti-viral immune responses
varies with the type and conditions of infection. Mice with a dis-
rupted gene for IFN-gR1 or IFN-g, or mice treated with anti-IFN-g
Ab, develop increased susceptibility to VV (59), ectromelia virus
(60), CMV (61), and mouse hepatitis virus (62, 63). In contrast,
control of acute infection with vesicular stomatitis virus (59), pseu-
dorabies virus (63), g-herpesvirus (64), and influenza virus (58) is
not dependent on IFN-g. Although IFN-g is thought to be crucial
FIGURE 5. VV-specific primary CTL responses. Mice were infected i.p. with 2 3 106 pfu of either VV-G2, VV-IL-4, or VV-IFN-g and sacrificed on
day 6 to collect spleens for determination of primary CTL activity by 51Cr release assay using MC57G fibroblasts infected with VV as target cells. Lysis
of uninfected MC57G targets was ,10%. Shown are values of the average of two mice. Data are representative of two separate experiments.
FIGURE 6. Characterization of lung pathology during VV infection.
C57BL/6 (A and C) and IL-122/2 mice (B) were infected i.p. with 2 3 106
pfu of either VV-G2 (A and B) or VV-IL-4 (C) and sacrificed on day 6 to
collect lungs for histological evaluation. Sections were stained with hemo-
toxylin and eosin.
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for the control of VV (4), we found that endogenous IL-12 is
superior to IFN-g for virus clearance. IFN-g2/2 mice showed sig-
nificantly increased susceptibility only to infection with VV strains
of low virulence such as VV (Lancy) (65) or recombinant VV (i.e.,
VV-G2, with a mutation of the tk gene). Clearance of a strain with
high virulence in mice was minimally affected by the absence of
IFN-g. In contrast, IL-12-deficient mice were much more suscep-
tible, independent of the virulence of the VV strain. It has been
shown that IL-12 treatment is beneficial for the host during infec-
tion with a variety of viruses, and that this effect is mediated pri-
marily through induction of IFN-g by NK cells and T cells (18, 20,
66, 67). Our results expand the host defense repertoire of IL-12
beyond the induction of IFN-g, the most widely studied antimi-
crobial action of IL-12 (68). In addition to inducing IFN-g, IL-12
has been shown to stimulate expression of TNF-a (69), which can
act by itself in the absence of IFN-g in the control of visceral
leishmaniasis (70). An important role of TNF-a and the two re-
ceptors TNFR-1 (p55) and TNFR-2 (p75) in the control of VV
replication has been demonstrated (57) .
CTL responses were abrogated in IL-122/2 mice but remained
normal in IFN-g2/2 mice after VV infection. These findings are in
concordance with those of others, who showed that in vitro CTL
generation was augmented by the addition of IL-12 in the presence
of neutralizing anti-IFN-g Abs (71). Unimpaired CTL generation
observed in IL-122/2 mice after immunization with allogeneic
cells (46) or with LCMV (M. van den Broek, unpublished obser-
vations) probably reflects the inability of these stimuli to induce
significant IL-12 levels in vivo (72) and an IL-12-independent
pathway for the induction of CTL responses. High and low sus-
ceptibility to VV correlates with the absence and presence of CTL
responses in IL-122/2 and IFN-g2/2 mice, respectively. This
may argue that defective CTL responses allow uncontrolled VV
replication in IL-122/2 mice. However, protection against acute
and challenge infection with VV, vesicular stomatitis virus, and
Semliki Forest virus (SFV) has been shown to be independent of
both perforin- and fas-dependent pathways suggesting that CD81
T cell cytotoxicity plays a limited if any role after infection with
cytopathic viruses (73).
Excess of IL-4 has been shown to be deleterious for the host in
various virus models (25, 27, 29) In particular, overexpression of
IL-4 at the site of infection using VV as a vector severely inhibits
host defense (25). In agreement with these results, we found that
C57BL/6 mice infected with recombinant VV-IL-4 developed lung
pathology and virus titers similar to IL-122/2 mice infected with
VV expressing an irrelevant control protein, suggesting that IL-
12-mediated protection is inhibited by IL-4. However, the finding
that VV-expressed IL-4 further increased viral spread in IL-122/2
mice argues that IL-4 has detrimental effects independent of IL-12
inhibition. Importantly, at physiological levels, IL-4 appears to
play a more limited role as an inhibitor of VV clearance, which is
dependent on the dose and virulence of the VV inoculate. Virus
titers were significantly decreased in IL-42/2 mice infected with
intermediate but not with low or high doses of VV (WR). Further-
more, infection with less virulent VV strains such as VV (Lancy)
(28) or recombinant derivatives (i.e., VV-G2) showed no evident
role for IL-4 in suppression of virus replication. Interestingly, we
found that the absence of IL-10 promoted the host defense much
stronger than the absence of IL-4. IL-102/2 mice showed mark-
edly diminished virus titers independent of the dose and virulence
of VV inoculate. Paradoxically, infection of mice with a recom-
binant VV-expressing murine IL-10 resulted in subtle in vivo dif-
ferences (32). IL-10 is known as a potent inhibitor of proinflam-
matory cytokines and IL-12 production by both macrophages and
dendritic cells in vitro (74, 75) and in vivo (76, 77). In agreement
with this, we demonstrated that splenocytes of VV-infected IL-
102/2 mice produced augmented levels of the proinflammatory
cytokines IL-1 and IL-6. Splenocyte cultures of infected IL-42/2
mice also contained elevated levels of the two proinflammatory
cytokines, which have been shown to be important for VV clear-
ance (78). In vivo, IL-10 is probably a more effective inhibitor of
VV clearance compared with IL-4, because it is secreted by acti-
vated macrophages and can act as an autocrine inhibitor immedi-
ately after infection, whereas IL-4 is produced mainly by Th2 cells
that develop later in infection.
Based on the findings that NO production is induced by type 1
cytokines (e.g., IFN-g) and inhibited by type 2 cytokines (IL-4,
IL-10, IL-13, TGF-b) (34), we hypothesized that the difference in
susceptibility of IL-122/2 and IFN-g2/2 vs IL-42/2 and IL-102/2
mice can be explained by altered regulation of NO. In fact, NO
excess has been demonstrated to inhibit VV replication in vitro
(39) and in vivo (40). Surprisingly, our results demonstrate that
NOS2-deficient mice cleared VV as well as controls, which is in
agreement with others showing that pharmacologic inhibition of
NO during VV infection did not alter the course of infection (41).
This argues that NO can exhibit potent anti-viral activity if ex-
pressed locally by recombinant VV, whereas it plays a limited if
any role during the normal course of VV infection. Our results
suggest that altered reactive nitrogen intermediates are not respon-
sible for the susceptibility and the resistance of IL-12- and IL-10-
deficient mice, respectively, to VV infection. The role of reactive
oxygen intermediates in this scenario remains to be tested.
Immune responses to viruses are dominated by Th1 cells that
provide help for anti-virus IgG2a responses and CTLs that kill
infected cells. In general, virus-specific CD81 T cells produce the
Th1-like cytokine pattern, i.e., IFN-g, LT-a, and TNF-a, and these
have been referred to as Tc1 cells. IL-12 has been shown to be a
critical factor for the development of Th1 cells in response to bac-
teria and parasites (17, 79). Less is known about the role of IL-12
for Th1 and Tc1 development after viral infection. A variety of
viruses have been shown to transiently increase the IL-12p40 gene
or stimulate IL-12p70 production shortly after infection (80–82).
However, IL-122/2 mice infected with mouse hepatitis virus (23)
or LCMV (24) show unaltered IFN-g and IL-4 responses in both
CD41 and CD81 T cells. Our data demonstrate that IL-12 is dis-
pensable for the development of both IFN-g-producing CD41 and
CD81 T cells after VV infection and that these cells also migrate
to sites of virus replication. In contrast, in the absence of IL-12, we
did find elevated Th2 cytokine production (i.e., IL-4 and IL-10)
after VV infection. Previously it has been suggested that the pres-
ence of IL-4 can induce secretion of type 2 cytokines by CD81 T
cells, which remain cytolytic or switch to noncytolytic Th cells
FIGURE 7. Unaltered VV clearance of NOS22/2 mice. Mice were in-
fected i.p. with 2 3 106 pfu of VV (WR) and sacrificed on day 6 to collect
ovaries for determination of virus titers. Shown are values of individual
mice. Data are representative of two separate experiments.
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dependent on the experimental system (83, 84). Our present results
suggest that CD81 Tc2 differentiation after viral infection is lim-
ited even when conditions appear favorable, i.e., the absence of
IL-12 and elevated IL-4 secretion by CD41 T cells. Moreover, our
results confirm that effector CD81 T cell cytolytic function ap-
pears not to be markedly affected by endogenous IL-4 levels as has
been shown for VV, LCMV, and Sendai virus infection (28, 30),
although the potential of IL-4, when present in excess, to inhibit
CTL responses was evident after infection with recombinant VV-
expressing IL-4 (25) or in IL-4 transgenic mice infected with re-
spiratory syncytial virus (29). Inhibition of CTL by endogenous
IL-4 may be more important during memory responses, as dem-
onstrated for respiratory syncytial virus (85) .
Together our studies exemplify cytokine-mediated control of a
cytopathic virus. IL-12 plays a dominant role in protective immu-
nity to acute VV. IL-12 activity goes beyond the induction IFN-g
and includes control of CTL responses and probably innate im-
munity, such as the production of inflammatory cytokines
(e.g.,TNF-a) and chemokines. These results warrant further stud-
ies with other cytolytic viruses such as influenza, which can be
effectively controlled in the absence of IFN-g (58). Endogenous
IL-4 and, in particular, IL-10 responses interfere with immunity to
VV, which can be explained by inhibition of the monokines IL-1,
IL-6, and IL-12. Excessive amounts of IL-4 expressed by recom-
binant VV shows a more dramatic role than its absence during
infection. Overexpression of IFN-g by recombinant VV at the site
of infection cures susceptible IL-122/2 mice (Fig. 4) and nude
mice (4), demonstrating the potent direct anti-viral activity of
IFN-g. However, endogenous IFN-g production is not crucial for
control of VV replication. Interestingly, studies with recombinant
VV vectors expressing IL-2 (86), TNF-a (87), CD40L (88), and
NOS2 (40) have all suggested a critical role for these factors in
resistance to VV. However, mice deficient for these genes cleared
VV normally (28, 57, 89) (Fig. 7). In contrast, the role of endog-
enous IL-10 as an inhibitor of virus clearance was undiscovered in
studies with recombinant VV-expressing IL-10. These results are
important for understanding the role of type 1 and type 2 cytokines
during infection with cytopathic viruses and for cytokine viral vec-
tor-based gene therapy and vaccination approaches.
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